ADAGE CAPITAL PARTNERS GP L.L.C. 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-07 07:37 am Sale | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 500,000 0.670% | -3,918,962 (-88.69%) | Filing |
| 2023-03-13 4:30 pm Purchase | 2023-03-01 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,418,962 5.940% | 1,818,962 (+69.96%) | Filing |
| 2023-02-09 11:04 am Sale | 2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,600,000 4.050% | -1,327,000 (-33.79%) | Filing |
| 2022-10-28 4:30 pm Purchase | 2022-10-18 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 3,927,000 6.140% | 2,624,508 (+201.50%) | Filing |
| 2022-02-10 11:11 am Sale | 2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,302,492 2.130% | -1,547,508 (-54.30%) | Filing |
| 2021-01-04 4:05 pm Purchase | 2020-12-24 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,850,000 5.580% | 2,850,000 (New Position) | Filing |